A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EVALUATE SAFETY AND EFFICACY OF OCRELIZUMAB IN COMPARISON WITH FINGOLIMOD IN CHILDREN AND ADOLESCENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Ocrelizumab (Primary) ; Fingolimod
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms Operetta 2
- Sponsors Roche
- 25 Apr 2024 Planned number of patients changed from 233 to 171.
- 31 Oct 2023 Planned End Date changed from 5 Nov 2025 to 17 Sep 2029.
- 14 Feb 2022 Planned End Date changed from 5 Nov 2029 to 5 Nov 2025.